Physician profile
John Meadows
NPI 1811952849
$203,503.46
in general payments reported to CMS, 2019-2025
30 companies · $838 in 2025
The $838 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $18K · 2021: $41K · 2022: $63K · 2023: $48K · 2024: $10K · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $19K · Food and Beverage: $4,587 · Travel and Lodging: $4,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,973.97 |
| Consulting Fee | $19,212.50 |
| Food and Beverage | $4,587.24 |
| Travel and Lodging | $4,557.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $54,061.32 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Teva Pharmaceuticals USA, INC. | $51,494.82 | 2019-2023 | Airduo Digihaler, Proair Digihaler, Armonair Digihaler |
| Regeneron Healthcare Solutions, INC. | $23,420.52 | 2019-2025 | Dupixent |
| Genzyme Corporation | $20,277.20 | 2019-2025 | |
| Pfizer INC. | $19,529.86 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16,770.54 | 2021-2025 | Cinryze, Takhzyro, Eohilia |
| Merck Sharp & Dohme LLC | $7,211.78 | 2021-2023 | |
| Optinose US, INC. | $5,000.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $2,406.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,071.72 | 2019-2024 | Nucala, Trelegy Ellipta |
| Alk-Abello, INC | $552.03 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $416.20 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $203.06 | 2019-2021 | |
| Kaleo, INC. | $188.88 | 2019-2023 | Auvi-Q |
| Csl Behring | $136.90 | 2019-2024 | Haegarda |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.08 | 2020-2021 | |
| Genentech USA, INC. | $121.74 | 2019-2024 | Xolair |
| Greer Laboratories, INC. | $110.64 | 2023-2025 | Oralair |
| Biocryst US Sales Co., LLC | $74.19 | 2025 | Orladeyo |
| Eyevance Pharmaceuticals LLC | $51.99 | 2020-2021 | |
| Lilly USA, LLC | $47.69 | 2025 | Ebglyss |
| Amgen INC. | $44.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $31.45 | 2021 | |
| Leo Pharma INC. | $27.79 | 2022 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Uswm, LLC | $25.00 | 2021 | |
| Ionis Pharmaceuticals, INC. | $24.96 | 2025 | Dawnzera |
| Melinta Therapeutics, LLC | $18.06 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Hikma Pharmaceuticals USA | $15.48 | 2023 | Ryaltris |
| Glaukos Corporation | $15.00 | 2023 | Photrexa Cross-Linking Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.